The estimated Net Worth of Jeffrey Duchemin is at least $3.05 Milhão dollars as of 10 April 2019. Jeffrey Duchemin owns over 19,157 units of Harvard Bioscience stock worth over $2,351,413 and over the last 11 years Jeffrey sold HBIO stock worth over $693,808.
Jeffrey has made over 10 trades of the Harvard Bioscience stock since 2015, according to the Form 4 filled with the SEC. Most recently Jeffrey sold 19,157 units of HBIO stock worth $86,398 on 10 April 2019.
The largest trade Jeffrey's ever made was exercising 150,000 units of Harvard Bioscience stock on 7 August 2018 worth over $646,500. On average, Jeffrey trades about 11,906 units every 44 days since 2013. As of 10 April 2019 Jeffrey still owns at least 830,888 units of Harvard Bioscience stock.
You can see the complete history of Jeffrey Duchemin stock trades at the bottom of the page.
Jeffrey's mailing address filed with the SEC is C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD, HOLLISTON, MA, 01746.
Over the last 21 years, insiders at Harvard Bioscience have traded over $10,145,146 worth of Harvard Bioscience stock and bought 754,658 units worth $2,380,232 . The most active insiders traders include Earl R Lewis, Bertrand Loy, eDavid Green. On average, Harvard Bioscience executives and independent directors trade stock every 43 days with the average trade being worth of $182,054. The most recent stock trade was executed by James W Green on 13 June 2024, trading 10,000 units of HBIO stock currently worth $29,100.
harvard bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. we sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including ge healthcare, thermo fisher scientific inc., and vwr. we have sales and manufacturing operations in the united states, the united kingdom, germany, and spain and sales facilities in france and canada.
Harvard Bioscience executives and other stock owners filed with the SEC include: